Last reviewed · How we verify

NCT05346289

Elective Treatment Rates and Surgical Non-eligibility Among Men and Women With Intact Abdominal Aortic Aneurysms

Completed Last updated 5 December 2022
What this trial tests

trial testing Elective surgery for intact AAA in Abdominal Aortic Aneurysm in 400 participants. Completed in 1 November 2022.

Timeline
1 June 2020
Primary endpoint
14 February 2022
1 November 2022

Quick facts

Lead sponsorKarolinska University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 June 2020
Primary completion14 February 2022
Estimated completion1 November 2022
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska University Hospital

Who can join

40 and older, any sex, with Abdominal Aortic Aneurysm or Abdominal Aortic Aneurysm Without Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim is to determine the frequency by which women and men with intact abdominal aortic aneurysms (AAA) are treated with elective surgery at three vascular outpatient clinics in Europe, and to investigate whether the reasons to refrain from elective surgery differ between the sexes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Women with large intact abdominal aortic aneurysms remain untreated.
    Talvitie M, Åldstedt-Nyrønning L, Stenman M, Roy J, et al · · 2023 · cited 5× · PMID 37211143 · DOI 10.1016/j.jvs.2023.05.025

Verify or expand the search:

Other recruiting trials for Abdominal Aortic Aneurysm

Currently open trials in the same condition.

Other Karolinska University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05346289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing